JASON ARDELEAN: Open Payments
NPI 1972195535 · OWOSSO, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$796 in 47 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $862 · 2025 $796
Food & beverage: $780Education: $16
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $234 |
| Janssen Biotech, Inc. | 12 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $87 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $81 |
| Regeneron Healthcare Solutions, Inc. | 2 | $55 |
| Ardelyx, Inc. | 2 | $38 |
| Janssen Scientific Affairs, LLC | 1 | $37 |
| Ipsen Biopharmaceuticals, Inc | 2 | $34 |
| Gilead Sciences, Inc. | 2 | $33 |
| Intercept Pharmaceuticals, Inc. | 1 | $20 |
Products named: TREMFYA, RINVOQ, XIFAXAN, DUPIXENT, SKYRIZI, MAVYRET, IBSRELA, ENTYVIO.
Industry payments across MI — which companies pay providers there.
